''Nilotinib, in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor...
It was approved as Tasigna in the USA and the EU for drug-resistant chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib, also known by its clinical code AMN107, has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment withimatinib (Gleevec), another tyrosine kinase inhibitor currently used as a first-line treatment. In that study 92% of patients (already resistant or unresponsive to Gleevec) achieved a normal white blood cell counts after five months of treatment... 'Extract of Wikipedia


Tasigna by Novartis
Nilotinib Information by Nilotinib.org
Tasigna by Drugs.com

Tasigna Talk by newcmldrug.com
Tasigna on Facebook.

Gary Gonzales - Tasigna patient video

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
July 5, 2012, PubLmed

Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.
May 24, 2012, Unbound Medline

Nilotinib-Associated Vascular Events.
May 23, 2012, PublMed

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete genetic response during first-line nilotinib therapy.
April 19, 2012, PubLMed

Clinical cardiac safety profile of nilotinib.
January 22, 2012, PubLMed

The Apothecary Shops Incorporates Innovative Technology Into Patient Medication Reminders

December 19, 2011, PRNewswire

FDA approves update for Tasigna label

December 15, 2011, Modern Medicine

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.

November 11, 2011, PubMed

Nilotinib Beats Imatinib at 24 Months in Treatment of CML
June 20, 2011, Medscape Today

Nilotinib Superior to Imatinib, Fewer Mutations in Treatment of CML-CP

June 6, 2011, Monthly Prescribing Reference

Nilotinib for Myeloid Leukemia
December 7, 2010, Oncology Stat

ASH 2010: Nilotinib promising for early chronic phase, Philidelphia-positive chronic myeloid leukaemia
December 4, 2010, Ecancermedicalscience

Nilotinib associated with stable outcomes in Ph+CML
December 4, 2010, ASH 2010, Orlando

Nilotinib Attenuates Renal Injury and Prolongs Survival in Chronic Kidney Disease
November 13, 2010, JASN

Living with chronic myeloid leukemia (Tasigna is approved in Canada) VIDEO
August 2010, Info4YourLife

Nilotinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia. F1000: Ranked "Exceptional" and "Changes Clinical Practice"
July 2010, Medscape Today

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
June 5, 2010, The New England Journal of Medecine

Tasigna versus Gleevec VIDEO
June 16, 2010, Insidermedecine

Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia
December 9, 2009, Insciences organisation

Nilotinib for the frontline treatment of Ph+ chronic leukemia
December 3, 2009, Blood, Vol.114, No.24, pp.493304938

EHA 2009: Nilotinib Superior in Chronic Myeloid Leukemia Than Current Standard
June 2009, Medscape

The Consumer Information Section (Part III) of the Product Monograph for TASIGNA
June 2009, Health Canada

Targeted therapies for CML: practical considerations and comparisons
August 10, 2008, HemOncToday

When Imatinib and Dasatinib Fail, Nilotinib May Be an Option for CML
April 2008, Clinical Oncology

Return to Chronic Myeloid Leukemia Home

Your Comments

Have your say about what you just read! Leave me a comment in the box below. I strongly appreciate all feedback :)

Get Our Newsletter

Enter Your E-mail Address
Enter Your Name (optional)

Don't worry — your e-mail address is totally secure.
I promise to use it only to send you CMLer.
Bookmark and Share